Sglt-2 inhibitors in type 1 diabetes mellitus: A comprehensive review of the literature

Current Clinical Pharmacology

Volumn 13, Issue 4, 2018, Pages 261-272

  Patoulias, Dimitrios ^a   Imprialos, Konstantinos ^a   Stavropoulos, Konstantinos ^a   Athyros, Vasilios ^a   Doumas, Michael ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Canagliflozin; Cardiovascular disease; Dapagliflozin; Empagliflozin; Ketoacidosis; SGLT 2 inhibitors; Type 1 dabetes mellitus

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; PLACEBO; REMOGLIFLOZIN ETABONATE; SOTAGLIFLOZIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ACUTE GASTROENTERITIS; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT LOSS; CARDIOVASCULAR EFFECT; CLINICAL PRACTICE; DIABETIC KETOACIDOSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; NONHUMAN; OFF LABEL DRUG USE; PATIENT SATISFACTION; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK FACTOR; BLOOD; CHEMICALLY INDUCED; GLUCOSE BLOOD LEVEL; METABOLISM; PHARMACOLOGY; PROCEDURES;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; GLUCOSIDES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85058852862     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574884713666180807150509     Document Type: Article

References (55)

1. Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 2017; 376(15): 1407-18.
2. Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence trends of type 1 and type 2 diabetes among youths. N Engl J Med 2017; 376(15): 1419-29.
3. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014; 371(21): 1972-82.
4. Andrade CS, Ribeiro GS, Santos CAST, Neves RCS, Moreira ED Jr. Factors associated with high levels of glycated haemoglobin in patients with type 1 diabetes: A multicentre study in Brazil. BMJ Open 2017; 7(12): e018094.
5. Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: Updated data from the T1D Exchange clinic registry. Diabetes Care 2015; 38(6): 971-8.
6. Stanton RC. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: Is there a role for SGLT2 inhibitors in diabetic kidney disease? Circulation 2014; 129(5): 542-4.
7. Gordin D, Groop PH. Aspects of hyperglycemia contribution to arterial stiffness and cardiovascular complications in patients with type 1 Diabetes. J Diabetes Sci Technol 2016; 10(5): 1059-64.
8. Muskiet MHA, Heerspink HJL, van Raalte DH. SGLT2 inhibition: A new era in renoprotective medicine? Lancet Diabetes Endocrinol 2017; 5(8): 569-71.
9. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG OUTCOME study. Diabetes Care 2016; 39(5): 717-25.
10. Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 2018; 137(2): 119-29.
11. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 Diabetes. N Engl J Med 2015; 373(22): 2117-28.
12. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 Diabetes. N Engl J Med 2016; 375(4): 323-34.
13. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 Diabetes. N Engl J Med 2017; 377(7): 644-57.
14. Birkeland KI, Jørgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): A multinational observational analysis. Lancet Diabetes Endocrinol 2017; 5(9): 709-17.
15. Vallianou NG, Geladari E, Kazazis CE. SGLT-2 inhibitors: Their pleiotropic properties. Diabetes Metab Syndr 2017; 11(4): 311-5.
16. Scheen AJ, Paquot N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence. Diabetes Metab 2014; 40(6)(Suppl. 1): S4-S11.
17. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129(5): 587-97.
18. Filippas-Ntekouan S, Filippatos TD, Elisaf MS. SGLT2 inhibitors: Are they safe? Postgrad Med 2018; 130(1): 72-82.
19. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPAREG OUTCOME trial: A “thrifty substrate” hypothesis. Diabetes Care 2016; 39(7): 1108-14.
20. Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. JAMA Cardiol 2017; 2(9): 1025-9.
21. Harjutsalo V, Thomas MC, Forsblom C, Groop PH. FinnDiane Study Group.. Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes. Diabetes Obes Metab 2018 Jul 2; [Accessed 19th June, 2018].
22. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015; 38(12): 2258-65.
23. Peters AL, Henry RR, Thakkar P, Tong C, Alba M. Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care 2016; 39(4): 532-8.
24. Rodbard HW, Peters AL, Slee A, Cao A, Traina SB, Alba M. The effect of Canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. Diabetes Care 2017; 40(2): 171-80.
25. Patel NS, Van Name MA, Cengiz E, et al. Altered patterns of early metabolic decompensation in type 1 Diabetes during treatment with a SGLT2 inhibitor: an insulin pump suspension study. Diabetes Technol Ther 2017; 19(11): 618-22.
26. Argento NB, Nakamura K. Glycemic effects of SGLT-2 inhibitor canagliflozin in type 1 diabetes patients using the DEXCOM G4 PLATINUM CGM. Endocr Pract 2016; 22(3): 315-22.
27. Guthrie R. Canagliflozin use in Type I diabetes mellitus. Postgrad Med 2017; 129(3): 336-9.
28. Tamez HE, Tamez AL, Garza LA, Hernandez MI, Polanco AC. Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 Diabetes mellitus. J Diabetes Metab Disord 2015; 14: 78.
29. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015; 38(3): 412-9.
30. Henry RR, Dandona P, Pettus J, Mudaliar S, Xu J, Hansen L. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study. Diabetes Obes Metab 2017; 19(6): 814-21.
31. Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5(11): 864-76.
32. Kuhadiya ND, Ghanim H, Mehta A, et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 Diabetes. J Clin Endocrinol Metab 2016; 101(9): 3506-15.
33. Biester T, Aschemeier B, Fath M, et al. Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes. Diabetes Obes Metab 2017; 19(11): 1635-9.
34. Tang W, Leil TA, Johnsson E, Boulton DW, LaCreta F. Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus. Diabetes Obes Metab 2016; 18(3): 236-40.
35. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014; 37(5): 1480-3.
36. Lamos EM, Younk LM, Davis SN. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs 2014; 23(6): 875-82.
37. Skrtić M, Yang GK, Perkins BA, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014; 57(12): 2599-602.
38. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014; 13: 28.
39. Perkins BA, Cherney DZ, Soleymanlou N, et al. Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes. PLoS One 2015; 10(11): e0141085.
40. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015; 17(10): 928-35.
41. Famulla S, Pieber TR, Eilbracht J, et al. Glucose exposure and variability with empagliflozin as adjunct to insulin in patients with type 1 Diabetes: continuous glucose monitoring data from a 4- week, randomized, placebo-controlled trial (EASE-1). Diabetes Technol Ther 2017; 19(1): 49-60.
42. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 Inhibitor, as adjunct therapy to insulin in type 1 Diabetes. Diabetes Care 2015; 38(7): 1181-8.
43. Garg SK, Henry RR, Banks P, et al. Effects of Sotagliflozin added to insulin in patients with type 1 Diabetes. N Engl J Med 2017; 377(24): 2337-48.
44. Mudaliar S, Armstrong DA, Mavian AA, et al. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care 2012; 35(11): 2198-200.
45. Yang Y, Pan H, Wang B, Chen S, Zhu H. Efficacy and safety of SGLT2 inhibitors in patients with type 1 Diabetes: A meta-analysis of randomized controlled trials. Chin Med Sci J 2017; 32(1): 22-7.
46. Chen J, Fan F, Wang JY, et al. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep 2017; 7: 44128.
47. Thrailkill KM, Nyman JS, Bunn RC, et al. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes. Bone 2017; 94: 141-51.
48. Terasaki M, Hiromura M, Mori Y, et al. Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 Diabetic mice. PLoS One 2015; 10(11): e0143396.
49. Leng W, Ouyang X, Lei X, et al. The SGLT-2 Inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic apoe-/- Mice. Mediators Inflamm 2016; 2016: 6305735.
50. Terasaki M, Hiromura M, Mori Y, et al. Combination therapy with a sodium-glucose cotransporter 2 inhibitor and a dipeptidyl peptidase- 4 inhibitor additively suppresses macrophage foam cell formation and atherosclerosis in diabetic mice. Int J Endocrinol 2017; 2017: 1365209.
51. Hatanaka T, Ogawa D, Tachibana H, et al. Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucoseinduced oxidative stress in type 1 diabetic mice. Pharmacol Res Perspect 2016; 4(4): e00239.
52. Cheng ST, Chen L, Li SY, Mayoux E, Leung PS. The Effects of Empagliflozin, an SGLT2 Inhibitor, on pancreatic β-Cell mass and glucose homeostasis in type 1 Diabetes. PLoS One 2016; 11(1): e0147391.
53. Luippold G, Klein T, Mark M, Grempler R. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes Metab 2012; 14(7): 601-7.
54. Tahara A, Kurosaki E, Yokono M, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocininduced type 1 diabetic rats. J Pharm Pharmacol 2014; 66(7): 975-87.
55. Powell DR, Doree D, Jeter-Jones S, Ding ZM, Zambrowicz B, Sands A. Sotagliflozin improves glycemic control in nonobese diabetes- prone mice with type 1 diabetes. Diabetes Metab Syndr Obes 2015; 8: 121-7.